| TAH Drug Code | ORIB |
|---|---|
| Indications | Treatment of psychoses, particularly acute or chronic schizophrenic disorders, characterized by +ve symptoms (e.g. delirium, hallucinations, thought disorders) &/or -ve symptoms (eg blunted emotions, emotional & social withdrawal), including when the -ve symptoms predominate. |
| Dosing | <=400 mg daily dose, single intake. >400 mg, in 2 divided doses. Predominant negative episode 50-300 mg/day as individualized dosage. Optimum dosage: 100 mg/day. Mixed episodes with positive & negative symptoms 400-800 mg/day as individualized dosage to maintain min effective dose. Acute psychotic episodes: Initiate with maximum 400 mg/day IM, replaced thereafter with 400-800 mg orally, maximum dosage: 1200 mg. Renal insufficiency CrCl 30-60 mL/min: reduce dose to 1/2. CrCl 10-30 mL/min: reduce dose to 1/3. |
| Hepatic Impairment | Dose adjustment not necessary |
| Renal Impairment | Dose adjustment required |
| Contraindications | Known or suspected pheochromocytoma carriers. Children < 15 years. Lactation. Known or suspected prolactin-dependent tumour, eg prolactin-secreting pituitary adenoma & breast cancer. Severe renal insufficiency. Congenital galactosemia, glucose or galactose malabsorption syndrome or lactase deficiency (due to lactose content). In combination with sultopride; dopaminergic agonists except L-dopa (amantadine, apomorphine, bromocriptine, cabergoline, entacapone, lisuride, pergolide, piribedil, pramipexole, quinagolide, ropinirole, selegiline), except in the case of patients with Parkinson's disease. |
| Adverse Effects | Common: Hypotension, Injection site pain (6%), Hypokalemia (4%), Prolactin level above reference range (5%), Abdominal distension symptom (2%), Shivering (4%) Serious: Prolonged QT interval |
| Pregnancy | Unknown |
| Lactation | Unknown |
| More Info | UpToDate |